Compare
Ardelyx, Inc. vs Zai Lab Ltd vs MannKind Corp vs Nature's Sunshine Products Inc
| Latest fiscal year | Ardelyx, Inc. ARDX | Zai Lab Ltd ZLAB | MannKind Corp MNKD | Nature's Sunshine Products Inc NATR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $407.32M | $457.18M | $348.97M | $480.14M |
| Revenue growth (YoY) | +22.1% | +15.0% | +22.2% | +5.7% |
| Gross margin | 90.3% (computed) | 58.3% (computed) | 92.3% (computed) | 72.4% |
| Operating margin | -10.1% | -50.2% | 11.1% | 5.2% |
| Net margin | -15.1% | -38.4% | 1.7% | 4.3% |
| Net income | -$61.60M | -$175.54M | $5.86M | $20.45M |
| EPS (Diluted) | -$0.26 | -$0.16 | $0.02 | $1.06 |
| Operating cash flow | -$42.48M | -$150.79M | $18.25M | $35.32M |
| Free cash flow | -$43.98M | -$158.89M | $13.69M | $28.84M |
| Cash & equivalents | $68.00M | $679.57M | $74.88M | $93.89M |
| Total assets | $501.60M | $1.17B | $792.18M | $261.15M |
| Total liabilities | $334.65M | $456.88M | $843.20M | $99.59M |
| Shareholders' equity | $166.95M | $715.50M | -$51.02M | $161.55M |
| Return on year-end equity | -36.9% | -24.5% | n/a | 12.7% |
| Shares outstanding | 244.35M | 1.11B | 307.83M | 17.51M |
Revenue, most recent five fiscal years
| Fiscal year | Ardelyx, Inc. | Zai Lab Ltd | MannKind Corp | Nature's Sunshine Products Inc |
|---|---|---|---|---|
| Latest | $407.32M Ended 2025-12-31 | $457.18M Ended 2025-12-31 | $348.97M Ended 2025-12-31 | $480.14M Ended 2025-12-31 |
| 1 year earlier | $333.62M Ended 2024-12-31 | $397.61M Ended 2024-12-31 | $285.50M Ended 2024-12-31 | $454.36M Ended 2024-12-31 |
| 2 years earlier | $124.46M Ended 2023-12-31 | $266.72M Ended 2023-12-31 | $198.96M Ended 2023-12-31 | $445.32M Ended 2023-12-31 |
| 3 years earlier | $52.16M Ended 2022-12-31 | $212.67M Ended 2022-12-31 | $99.77M Ended 2022-12-31 | $421.91M Ended 2022-12-31 |
| 4 years earlier | $10.10M Ended 2021-12-31 | $144.10M Ended 2021-12-31 | $75.44M Ended 2021-12-31 | $444.08M Ended 2021-12-31 |